(Q53247635)

English

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

scientific article published in June 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

phase II clinical trial

0 references

quality of life

1 reference

based on heuristic

inferred from title

polycythemia vera

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

Hans K. Hasselbalch

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

9

object named as

Heike L Pahl

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

author name string

Jan Samuelsson

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Oystein Bruserud

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Snezana Temerinac

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Yvonne Brandberg

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Mats Merup

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Olle Linder

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Magnus Bjorkholm

8

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Gunnar Birgegard

10

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Nordic Study Group for Myeloproliferative Disorders

11

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

language of work or name

0 references

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

106

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

11

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

2397-2405

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Interferon alpha in the treatment of polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Health-related quality of life measured by the EORTC QLQ-C30--reference values from a large sample of Swedish population.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Anagrelide treatment in 52 patients with chronic myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Long-term interferon therapy for thrombocytosis in myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

21 January 2018

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha in the treatment of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

7 January 2021

based on heuristic

inferred from DOI database lookup

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21900

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21900

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/16639737

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53247635&oldid=1795100489"